Understanding and correctly predicting safety, efficacy, DDI and formulation are critical to drug development. Existing preclinical models are not ideal predictors of pharmacokinetics and toxicity in humans. For example, current efflux assays rely on wild type rats dosed with chemical inhibitors. These chemical inhibitors often interact with multiple transporters — which increases the number of animals and studies needed.
|Currently Available Drug Transporter Rats:|